DeVere White RW - Search Results

1

MicroRNAs and their potential for translation in prostate cancer.

DeVere White RW, Vinall RL, Tepper CG, Shi XB. DeVere White RW, et al. Urol Oncol. 2009 May-Jun;27(3):307-11. doi: 10.1016/j.urolonc.2009.01.004. Urol Oncol. 2009. PMID: 19414119 Free PMC article.

2

Flow cytometry as a predictive modality in prostate cancer.

Deitch AD, deVere White RW. Deitch AD, et al. Among authors: devere white rw. Hum Pathol. 1992 Apr;23(4):352-9. doi: 10.1016/0046-8177(92)90081-d. Hum Pathol. 1992. PMID: 1563735 Review.

3

Quantitation of NM23 expression in human prostate tissues.

Fishman JR, Gumerlock PH, Meyers FJ, deVere White RW. Fishman JR, et al. Among authors: devere white rw. J Urol. 1994 Jul;152(1):202-7. doi: 10.1016/s0022-5347(17)32862-8. J Urol. 1994. PMID: 7515452

4

Molecular biology of prostate cancer.

Shi XB, Gumerlock PH, deVere White RW. Shi XB, et al. Among authors: devere white rw. World J Urol. 1996;14(5):318-28. doi: 10.1007/BF00184605. World J Urol. 1996. PMID: 8912472 Review.

5

Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.

Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Shi XB, et al. Among authors: devere white rw. Diagn Mol Pathol. 1996 Dec;5(4):271-8. doi: 10.1097/00019606-199612000-00008. Diagn Mol Pathol. 1996. PMID: 8955619

6

p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.

Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. Gumerlock PH, et al. Among authors: devere white rw. J Natl Cancer Inst. 1997 Jan 1;89(1):66-71. doi: 10.1093/jnci/89.1.66. J Natl Cancer Inst. 1997. PMID: 8978408

7

Human androgen receptor expression in prostate cancer following androgen ablation.

de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH. de Vere White R, et al. Eur Urol. 1997;31(1):1-6. doi: 10.1159/000474409. Eur Urol. 1997. PMID: 9032526

8

Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade.

Mack PC, Chi SG, Meyers FJ, Stewart SL, deVere White RW, Gumerlock PH. Mack PC, et al. Among authors: devere white rw. Prostate. 1998 Feb 1;34(2):145-51. doi: 10.1002/(sici)1097-0045(19980201)34:2<145::aid-pros10>3.0.co;2-i. Prostate. 1998. PMID: 9465946

9

Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions.

deVere White RW, Deitch AD, Gumerlock PH, Shi XB. deVere White RW, et al. Prostate. 1999 Oct 1;41(2):134-42. doi: 10.1002/(sici)1097-0045(19991001)41:2<134::aid-pros8>3.0.co;2-e. Prostate. 1999. PMID: 10477910 Review.

10

BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents.

Shi XB, Gumerlock PH, Muenzer JT, deVere White RW. Shi XB, et al. Among authors: devere white rw. Cancer Biother Radiopharm. 2001 Oct;16(5):421-9. doi: 10.1089/108497801753354320. Cancer Biother Radiopharm. 2001. PMID: 11776759

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters